So the results from the DNL747 phase 1 trial will likely generate some interest in the neurology research world. Denali says it will provide more details ... read more
Denali and Sanofi to press forward with RIPK1 drug in Alzheimer's and other brain diseases
Denali and Sanofi to press forward with RIPK1 drug in Alzheimer’s and other brain diseases